Welcome to the international HTA database

Showing [16861 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2020	NIHR Health Technology Assessment programme	Positron emission tomography to image cerebral neuroinflammation in ischaemic stroke: a pilot study
2020	Agency for Care Effectiveness (ACE)	Vonoprazan for treating helicobacter pylori infection
2020	National Institute for Health and Care Excellence (NICE)	Patiromer for treating hyperkalaemia. NICE technology appraisal guidance 623
2020	Agency for Care Effectiveness (ACE)	Blinatumomab for treating relapsed or refractory B-precursor acute lymphoblastic leukaemia
2020	National Institute for Health and Care Excellence (NICE)	Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 624
2020	Agency for Care Effectiveness (ACE)	Trastuzumab for treating HER2-positive breast and gastric cancers
2020	National Institute for Health and Care Excellence (NICE)	Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal). NICE technology appraisal guidance 625
2020	Agency for Care Effectiveness (ACE)	Antiretroviral therapies for treating human immunodeficiency virus type 1 (HIV-1) infection
2020	National Institute for Health and Care Excellence (NICE)	Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure. NICE technology appraisal guidance 626
2020	Agency for Care Effectiveness (ACE)	Benralizumab, mepolizumab and omalizumab for treating severe asthma
2020	National Institute for Health and Care Excellence (NICE)	Lenalidomide with rituximab for previously treated follicular lymphoma. NICE technology appraisal guidance 627
2020	NIHR Health Technology Assessment programme	Dementia Care Mapping to reduce agitation in care home residents with dementia: the EPIC cluster RCT
2020	NIHR Health Services and Delivery Research programme	Understanding and improving experiences of care in hospital for people living with dementia, their carers and staff: three systematic reviews
2020	Agency for Care Effectiveness (ACE)	Mycophenolate mofetil for immunosuppression
2020	Agency for Healthcare Research and Quality (AHRQ)	Strategies for patient, family, and caregiver engagement
2020	National Institute for Health and Care Excellence (NICE)	Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 628
2020	Agency for Care Effectiveness (ACE)	Adalimumab for treating inflammatory conditions
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Paediatric cardiac surgery - literature review
2020	National Institute for Health and Care Excellence (NICE)	Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab. NICE technology appraisal guidance 629
2020	NIHR Health Technology Assessment programme	Home-based narrowband UVB, topical corticosteroid or combination for children and adults with vitiligo: HI-Light Vitiligo three-arm RCT
2020	Agency for Care Effectiveness (ACE)	Abiraterone for treating metastatic prostate cancer
2020	National Institute for Health and Care Excellence (NICE)	Larotrectinib for treating NTRK fusion-positive solid tumours. NICE technology appraisal guidance 630
2020	National Institute for Health and Care Excellence (NICE)	Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer. NICE technology appraisal guidance 632
2020	National Institute for Health and Care Excellence (NICE)	Ustekinumab for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 633
2020	NIHR Health Technology Assessment programme	Stratified Care for Patients with Sciatica and Suspected Sciatica in Primary Care: a randomised trial (the SCOPiC trial - SCiatica Outcomes in Primary Care)
2020	NIHR Health Technology Assessment programme	Medically unexplained symptoms(MUS): primary care intervention
2020	Austrian Institute for Health Technology Assessment (AIHTA)	Effectiveness of Music Therapy for Autism Spectrum Disorder, Dementia, Depression, Insomnia and Schizophrenia
2020	National Institute for Health and Care Excellence (NICE)	Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal). NICE technology appraisal guidance 634
2020	Agency for Healthcare Research and Quality (AHRQ)	Therapies for clinically localized prostate cancer
2020	National Institute for Health and Care Excellence (NICE)	Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 635
2020	NIHR Health Technology Assessment programme	A randomised parallel group double blind placebo-controlled dose ranging Trial of low dose adjunctive alTeplase during priMary PCI (T-TIME)
2020	National Institute for Health and Care Excellence (NICE)	Eculizumab for treating refractory myasthenia gravis (terminated appraisal). NICE technology appraisal guidance 636
2020	National Institute for Health and Care Excellence (NICE)	Ranibizumab for treating diabetic retinopathy (terminated appraisal). NICE technology appraisal guidance 637
2020	National Institute for Health and Care Excellence (NICE)	Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer. NICE technology appraisal guidance 638
2020	NIHR Health Technology Assessment programme	Pre-Operative Behavioural Intervention to Reduce Drinking before elective orthopaedic Surgery (Pre-Op BIRDS)
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Betibeglogene autotemcel (β-thalassaemia) (treatment costs)]
2020	National Institute for Health and Care Excellence (NICE)	Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer. NICE technology appraisal guidance 639
2020	NIHR Health Technology Assessment programme	Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT
2020	NIHR Health Technology Assessment programme	Cancer diagnostic tools to aid decision-making in primary care: mixed-methods systematic reviews and cost-effectiveness analysis
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Adverse effects of messenger RNA vaccines
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Amnion membrane for topical treatment of ophthalmic disorders, wound dressings for skin burns and ulcers on the craniofacial area, torso, and limbs
2020	Agency for Healthcare Research and Quality (AHRQ)	Treatment of depression in children and adolescents
2020	National Institute for Health and Care Excellence (NICE)	Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant. NICE technology appraisal guidance 640
2020	National Institute for Health and Care Excellence (NICE)	Testing strategies for Lynch syndrome in people with endometrial cancer. NICE diagnostics guidance 42
2020	NIHR Health Services and Delivery Research programme	Identifying appropriate symbol communication aids for children who are non-speaking: enhancing clinical decision making
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Antibiotic prophylaxis for lower extremity wound debridement in the outpatient setting
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Alpha-1-antitrypsin genotyping
2020	National Institute for Health and Care Excellence (NICE)	Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma. NICE technology appraisal guidance 641
2020	National Institute for Health and Care Excellence (NICE)	Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke. NICE diagnostics guidance 41
2020	NIHR Health Technology Assessment programme	Surgical fixation compared with cast immobilisation for adults with a bicortical fracture of the scaphoid waist: the SWIFFT RCT
2020	NIHR Health Technology Assessment programme	What is the effectiveness of varenicline compared with nicotine replacement therapy for long term smoking cessation and clinically important outcomes such as mortality, myocardial infarction and frequency of service use? Evidence from the Clinical Practice Research Datalink
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Point of care vascular ultrasound
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	PSMA PET/CT imaging for informing treatment of patients with prostate cancer
2020	Agency for Healthcare Research and Quality (AHRQ)	Treatments for acute pain: a systematic review
2020	National Institute for Health and Care Excellence (NICE)	Gilteritinib for treating relapsed or refractory acute myeloid leukaemia. NICE technology appraisal guidance 642
2020	National Institute for Health and Care Excellence (NICE)	High-sensitivity troponin tests for the early rule out of NSTEMI. NICE diagnostics guidance 40
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Early mobilization to reduce medical inpatient length of stay and adverse
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Arthroscopic injection of a bioadhesive hydrogel implant (JointRep), in conjunction with microfracture, for treatment of osteochondral defects of the knee
2020	National Institute for Health and Care Excellence (NICE)	Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 643
2020	National Institute for Health and Care Excellence (NICE)	Tests to help assess risk of acute kidney injury for people being considered for critical care admission (ARCHITECT and Alinity i Urine NGAL assays, BioPorto NGAL test and NephroCheck test). NICE diagnostics guidance 39
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Review of immunoglobulin use for primary immunodeficiency diseases with antibody deficiency
2020	National Institute for Health and Care Excellence (NICE)	Entrectinib for treating NTRK fusion-positive solid tumours. NICE technology appraisal guidance 644
2020	NIHR Health Services and Delivery Research programme	Identifying nurse-staffing requirements using the Safer Nursing Care Tool. Modelling the costs and consequences of real world application to address variation in patient need on hospital wards
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Burosumab (reassessment after the deadline: hypophosphataemia)]
2020	National Institute for Health and Care Excellence (NICE)	Avelumab with axitinib for untreated advanced renal cell carcinoma. NICE technology appraisal guidance 645
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Burosumab (new therapeutic indication: X-linked hypophosphataemia, ≥ 18 years)]
2020	National Institute for Health and Care Excellence (NICE)	Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal). NICE technology appraisal guidance 646
2020	NIHR Health Technology Assessment programme	Seasonal Influenza Vaccination Effectiveness II (SIVE II): use of a large national primary care and laboratory-linked dataset to evaluate live attenuated and trivalent inactivated influenza vaccination effectiveness
2020	NIHR Public Health Research (PHR) programme	Feasibility study of how best to engage obese men in narrative SMS (short message system) and incentive interventions for weight loss, to inform a future effectiveness and cost-effectiveness trial
2020	NIHR Health Technology Assessment programme	Point-of-care creatinine tests to assess kidney function for outpatients requiring contrast-enhanced CT imaging: systematic reviews and economic evaluation
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Cannabidiol - reassessment after expiry of the deadline (Dravet-Syndrome, ≥ 2 years, combination with clobazam)]
2020	National Institute for Health and Care Excellence (NICE)	Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal). NICE technology appraisal guidance 647
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Cannabidiol - reassessment after expiry of the deadline (Lennox-Gastaut-Syndrome, ≥ 2 years, combination with clobazam)]
2020	National Institute for Health and Care Excellence (NICE)	Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal). NICE technology appraisal guidance 648
2020	National Institute for Health and Care Excellence (NICE)	Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma. NICE technology appraisal guidance 649
2020	NIHR Public Health Research (PHR) programme	Healthy Dads, Healthy Kids UK: a cultural adaptation and feasibility study of a weight management programme for fathers of younger children
2020	National Institute for Health and Care Excellence (NICE)	Pembrolizumab with axitinib for untreated advanced renal cell carcinoma. NICE technology appraisal guidance 650
2020	NIHR Health Services and Delivery Research programme	An evaluation of alcohol treatment centres: implications for service delivery, patient benefit and harm reduction
2020	Swiss Federal Office of Public Health (FOPH)	Glinides and glitazones in the treatment of type 2 diabetes
2020	National Institute for Health and Care Excellence (NICE)	Naldemedine for treating opioid-induced constipation. NICE technology appraisal guidance 651
2020	NIHR Health Technology Assessment programme	Spironolactone to improve exercise tolerance in people with permanent atrial fibrillation and preserved ejection fraction: the IMPRESS-AF RCT
2020	National Institute for Health and Care Excellence (NICE)	Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 653
2020	NIHR Health Technology Assessment programme	Examining the benefit of graduated compression stockings as an adjunct to low dose low molecular weight heparin in the prevention of venous thromboembolism in elective surgical inpatients identified as moderate or high risk for venous thromboembolism a multi-centre randomised controlled trial
2020	National Institute for Health and Care Excellence (NICE)	Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer. NICE technology appraisal guidance 654
2020	NIHR Health Services and Delivery Research programme	Understanding how frontline staff use patient experience data for service improvement - an exploratory case study evaluation and national survey (US-PEx)
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Amnion membrane for topical treatment of ophthalmic disorders (caused by disease and/or trauma), and wound dressings for skin burns and ulcers on the craniofacial area, torso, and limbs
2020	National Institute for Health and Care Excellence (NICE)	Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy. NICE technology appraisal guidance 655
2020	NIHR Health Services and Delivery Research programme	Young people with Attention Deficit Hyperactivity Disorder (ADHD) in transition from children's services to adult services (Catch-uS): a mixed methods project using national surveillance, qualitative and mapping studies
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Gilteritinib (Relapsed or Refractory Acute Myeloid Leukaemia with an FLT3 Mutation)]
2020	National Institute for Health and Care Excellence (NICE)	Siponimod for treating secondary progressive multiple sclerosis. NICE technology appraisal guidance 656
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Givosiran (acute hepatic porphyria, ≥ 12 years)]
2020	National Institute for Health and Care Excellence (NICE)	Carfilzomib for previously treated multiple myeloma. NICE technology appraisal guidance 657
2020	National Institute for Health and Care Excellence (NICE)	Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma. NICE technology appraisal guidance 658
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Review of immunoglobulin use for primary immunodeficiency diseases with antibody deficiency
2020	National Institute for Health and Care Excellence (NICE)	Galcanezumab for preventing migraine. NICE technology appraisal guidance 659
2020	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Pharmacological treatment of common pain conditions in older persons]
2020	National Institute for Health and Care Excellence (NICE)	Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer. NICE technology appraisal guidance 660
2020	National Institute for Health and Care Excellence (NICE)	Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma. NICE technology appraisal guidance 661
2020	European Network for Health Technology Assessment (EUnetHTA)	Polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant
2020	National Institute for Health and Care Excellence (NICE)	Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 662